PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 30578970-3 2019 We found that compared with the blank control group, expression of SIRT1 was decreased in the isoniazid group and that expression of NF-kappaB p65 was increased, leading to an increase of the expression of inflammatory cytokines Interleukin-6 (IL-6) and Tumour necrosis factor alpha (TNF-alpha). Isoniazid 94-103 tumor necrosis factor Homo sapiens 284-293 30964811-1 2019 OBJECTIVES: Isoniazid (INH) prophylaxis is recommended for the prevention of tuberculosis (TB) reactivation before or/and during initiation of treatment with tumour necrosis factor antagonists (anti-TNF agents). Isoniazid 12-21 tumor necrosis factor Homo sapiens 199-202 24464437-10 2015 A short course treatment with isoniazid and rifampin provided efficacy, good tolerability and good completion rate in patients with rheumatic conditions proposed for anti-TNF therapy. Isoniazid 30-39 tumor necrosis factor Homo sapiens 171-174 28288508-0 2018 Isoniazid treatment for latent tuberculosis infection is tolerable for rheumatoid arthritis patients receiving tumor necrosis factor inhibitor therapy. Isoniazid 0-9 tumor necrosis factor Homo sapiens 111-132 28288508-1 2018 BACKGROUND/AIMS: To evaluate the impact of isoniazid (INH) treatment for latent tuberculosis infection (LTBI) on the development of liver function test (LFT) abnormality and the persistence of tumor necrosis factor (TNF) inhibitors in rheumatoid arthritis (RA) patients. Isoniazid 43-52 tumor necrosis factor Homo sapiens 193-214 28288508-1 2018 BACKGROUND/AIMS: To evaluate the impact of isoniazid (INH) treatment for latent tuberculosis infection (LTBI) on the development of liver function test (LFT) abnormality and the persistence of tumor necrosis factor (TNF) inhibitors in rheumatoid arthritis (RA) patients. Isoniazid 43-52 tumor necrosis factor Homo sapiens 216-219 30052856-10 2018 One case of active TB [isoniazid-resistant strain] occurred in a patient with positive baseline TST receiving anti-TNF [0.05 events/100 patient-years]. Isoniazid 23-32 tumor necrosis factor Homo sapiens 115-118 21482342-6 2011 Anti-TNF therapy was stopped even though the patient had received 3 months of prophylactic treatment with rifampicin and isoniazid before starting etanercept. Isoniazid 121-130 tumor necrosis factor Homo sapiens 5-8 27708877-0 2014 Does isoniazid chemoprophylaxis increase the frequency of hepatotoxicity in patients receiving anti-TNF-alpha agent with a disease-modifying antirheumatic drug? Isoniazid 5-14 tumor necrosis factor Homo sapiens 100-109 27708877-1 2014 OBJECTIVE: The aim of this study is to determine the incidence of isoniazid (INH)-related hepatotoxicity in patients with rheumatologic diseases receiving tumor necrosis factor-alpha (TNF-alpha) antagonists along with a disease-modifying antirheumatic drug (DMARD). Isoniazid 66-75 tumor necrosis factor Homo sapiens 155-182 27708877-1 2014 OBJECTIVE: The aim of this study is to determine the incidence of isoniazid (INH)-related hepatotoxicity in patients with rheumatologic diseases receiving tumor necrosis factor-alpha (TNF-alpha) antagonists along with a disease-modifying antirheumatic drug (DMARD). Isoniazid 66-75 tumor necrosis factor Homo sapiens 184-193 18208824-4 2008 RESULTS: After standard screening, 15% of patients receiving TNF-alpha-blocking therapy were pretreated with isoniazide (INH), another 5% of patients did not receive TNF-alpha-blocking therapy because of LTBI. Isoniazid 109-119 tumor necrosis factor Homo sapiens 61-70 21125170-3 2010 We describe the case of a patient with PA refractory to disease-modifying drugs, who developed drug-induced hepatitis after chemoprophylaxis with isoniazid, administered prior to the treatment with an anti-TNFalpha agent. Isoniazid 146-155 tumor necrosis factor Homo sapiens 206-214 17332973-0 2007 Isoniazid intervention for latent tuberculosis among 86 patients with rheumatologic disease administered with anti-TNFalpha. Isoniazid 0-9 tumor necrosis factor Homo sapiens 115-123 17332973-1 2007 In this study, we investigated the safety and toxicity of isoniazid (INH) intervention therapy to the patients with latent tuberculosis who were given tumor necrosis factor alpha (TNFalpha) for the treatment of their rheumatologic diseases. Isoniazid 58-67 tumor necrosis factor Homo sapiens 151-178 17332973-1 2007 In this study, we investigated the safety and toxicity of isoniazid (INH) intervention therapy to the patients with latent tuberculosis who were given tumor necrosis factor alpha (TNFalpha) for the treatment of their rheumatologic diseases. Isoniazid 58-67 tumor necrosis factor Homo sapiens 180-188 34504225-0 2021 Association between 9-month isoniazid prophylaxis of latent tuberculosis and severe hepatitis in patients treated with TNF inhibitors. Isoniazid 28-37 tumor necrosis factor Homo sapiens 119-122 34642380-0 2021 Publisher Correction: Association between 9-month isoniazid prophylaxis of latent tuberculosis and severe hepatitis in patients treated with TNF inhibitors. Isoniazid 50-59 tumor necrosis factor Homo sapiens 141-144 31615316-0 2020 Should isoniazid prophylaxis be prescribed to the patients under tumor necrosis factor-alpha antagonists independent of tuberculin skin test? Isoniazid 7-16 tumor necrosis factor Homo sapiens 65-92